skip to Main Content

Patient-Derived Organoids Predict Chemotherapy Efficacy for Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Patient-derived cancer organoids are miniature tumors grown in the lab from donated tissue. A study presented by Dr. Matthew Weiss, professor at the Feinstein Institutes for Medical Research and deputy physician-in-chief and director of the surgical oncology program at Northwell Cancer Institute, has shown how these organoids can be generated from patients – regardless of the tumor stage – and used to predict chemotherapy efficacy.

Technology Networks had the pleasure of talking to Weiss to learn more about patient-derived organoids and how these disease models could be used to develop personalized treatment strategies for pancreatic cancer. Read more . . . 


Back To Top